BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

370 related articles for article (PubMed ID: 9419975)

  • 1. Epiregulin binds to epidermal growth factor receptor and ErbB-4 and induces tyrosine phosphorylation of epidermal growth factor receptor, ErbB-2, ErbB-3 and ErbB-4.
    Komurasaki T; Toyoda H; Uchida D; Morimoto S
    Oncogene; 1997 Dec; 15(23):2841-8. PubMed ID: 9419975
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The oncogenic ErbB-2/ErbB-3 heterodimer is a surrogate receptor of the epidermal growth factor and betacellulin.
    Pinkas-Kramarski R; Lenferink AE; Bacus SS; Lyass L; van de Poll ML; Klapper LN; Tzahar E; Sela M; van Zoelen EJ; Yarden Y
    Oncogene; 1998 Mar; 16(10):1249-58. PubMed ID: 9546426
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prolactin modulates phosphorylation, signaling and trafficking of epidermal growth factor receptor in human T47D breast cancer cells.
    Huang Y; Li X; Jiang J; Frank SJ
    Oncogene; 2006 Dec; 25(58):7565-76. PubMed ID: 16785991
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential heat stress stability of epidermal growth factor receptor and erbB-2 receptor tyrosine kinase activities.
    Liu SM; Carpenter G
    J Cell Physiol; 1993 Nov; 157(2):237-42. PubMed ID: 7901224
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phosphatidylinositol 3-kinase recruitment by p185erbB-2 and erbB-3 is potently induced by neu differentiation factor/heregulin during mitogenesis and is constitutively elevated in growth factor-independent breast carcinoma cells with c-erbB-2 gene amplification.
    Ram TG; Ethier SP
    Cell Growth Differ; 1996 May; 7(5):551-61. PubMed ID: 8732665
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Insulin-like growth factor and epidermal growth factor independence in human mammary carcinoma cells with c-erbB-2 gene amplification and progressively elevated levels of tyrosine-phosphorylated p185erbB-2.
    Ram TG; Dilts CA; Dziubinski ML; Pierce LJ; Ethier SP
    Mol Carcinog; 1996 Mar; 15(3):227-38. PubMed ID: 8597535
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epidermal growth factor and betacellulin mediate signal transduction through co-expressed ErbB2 and ErbB3 receptors.
    Alimandi M; Wang LM; Bottaro D; Lee CC; Kuo A; Frankel M; Fedi P; Tang C; Lippman M; Pierce JH
    EMBO J; 1997 Sep; 16(18):5608-17. PubMed ID: 9312020
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of herstatin, an autoinhibitor of HER-2/neu, inhibits transactivation of HER-3 by HER-2 and blocks EGF activation of the EGF receptor.
    Azios NG; Romero FJ; Denton MC; Doherty JK; Clinton GM
    Oncogene; 2001 Aug; 20(37):5199-209. PubMed ID: 11526509
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Betacellulin activates the epidermal growth factor receptor and erbB-4, and induces cellular response patterns distinct from those stimulated by epidermal growth factor or neuregulin-beta.
    Riese DJ; Bermingham Y; van Raaij TM; Buckley S; Plowman GD; Stern DF
    Oncogene; 1996 Jan; 12(2):345-53. PubMed ID: 8570211
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induction of cancer cell migration by epidermal growth factor is initiated by specific phosphorylation of tyrosine 1248 of c-erbB-2 receptor via EGFR.
    Dittmar T; Husemann A; Schewe Y; Nofer JR; Niggemann B; Zänker KS; Brandt BH
    FASEB J; 2002 Nov; 16(13):1823-5. PubMed ID: 12354693
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ErbB kinases and NDF signaling in human prostate cancer cells.
    Grasso AW; Wen D; Miller CM; Rhim JS; Pretlow TG; Kung HJ
    Oncogene; 1997 Nov; 15(22):2705-16. PubMed ID: 9400997
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides.
    Motoyama AB; Hynes NE; Lane HA
    Cancer Res; 2002 Jun; 62(11):3151-8. PubMed ID: 12036928
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ErbB-2 is a common auxiliary subunit of NDF and EGF receptors: implications for breast cancer.
    Karunagaran D; Tzahar E; Beerli RR; Chen X; Graus-Porta D; Ratzkin BJ; Seger R; Hynes NE; Yarden Y
    EMBO J; 1996 Jan; 15(2):254-64. PubMed ID: 8617201
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An unexpected biochemical and functional interaction between gp130 and the EGF receptor family in breast cancer cells.
    Grant SL; Hammacher A; Douglas AM; Goss GA; Mansfield RK; Heath JK; Begley CG
    Oncogene; 2002 Jan; 21(3):460-74. PubMed ID: 11821958
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Feedback inhibition by RALT controls signal output by the ErbB network.
    Anastasi S; Fiorentino L; Fiorini M; Fraioli R; Sala G; Castellani L; Alemà S; Alimandi M; Segatto O
    Oncogene; 2003 Jul; 22(27):4221-34. PubMed ID: 12833145
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human corneal epithelial cell proliferation by epiregulin and its cross-induction by other EGF family members.
    Morita S; Shirakata Y; Shiraishi A; Kadota Y; Hashimoto K; Higashiyama S; Ohashi Y
    Mol Vis; 2007 Nov; 13():2119-28. PubMed ID: 18079685
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bivalence of EGF-like ligands drives the ErbB signaling network.
    Tzahar E; Pinkas-Kramarski R; Moyer JD; Klapper LN; Alroy I; Levkowitz G; Shelly M; Henis S; Eisenstein M; Ratzkin BJ; Sela M; Andrews GC; Yarden Y
    EMBO J; 1997 Aug; 16(16):4938-50. PubMed ID: 9305636
    [TBL] [Abstract][Full Text] [Related]  

  • 18. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.
    Traxler P; Allegrini PR; Brandt R; Brueggen J; Cozens R; Fabbro D; Grosios K; Lane HA; McSheehy P; Mestan J; Meyer T; Tang C; Wartmann M; Wood J; Caravatti G
    Cancer Res; 2004 Jul; 64(14):4931-41. PubMed ID: 15256466
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recombinant heregulin-Pseudomonas exotoxin fusion proteins: interactions with the heregulin receptors and antitumor activity in vivo.
    Yang D; Kuan CT; Payne J; Kihara A; Murray A; Wang LM; Alimandi M; Pierce JH; Pastan I; Lippman ME
    Clin Cancer Res; 1998 Apr; 4(4):993-1004. PubMed ID: 9563895
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epidermal growth factor receptor (EGFR) signaling in cancer.
    Normanno N; De Luca A; Bianco C; Strizzi L; Mancino M; Maiello MR; Carotenuto A; De Feo G; Caponigro F; Salomon DS
    Gene; 2006 Jan; 366(1):2-16. PubMed ID: 16377102
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.